06955 BOAN BIOTECH
- 9.150
- +0.030+0.33%
BOAN BIOTECH News
Shandong Boan Biotechnology Swings to Profit in H1
Boan Biotechnology announced its interim results, with a shareholder's share of profit attributable to RMB 61.672 million, turning losses into profits year on year.
Boan Biotech (06955) released its financial results for the six months ending on June 30, 2024, with a total revenue of 0.363 billion yuan (RMB) in the period, an increase of 38.93% year-on-year. The net profit attributable to the owners of the parent company was 61.672 million yuan, while in the same period last year, the net loss attributable to the owners of the parent company was 0.12 billion yuan. The basic earnings per share were 0.12 yuan.
Boan Biotech Reports Strong Mid-Year Financial Growth
Bo'an Biology (06955.HK) recorded approximately 0.363 billion yuan in interim revenue, a year-on-year growth of 38.9%.
The announcement of Boan Biological (06955.HK) on August 27th shows that as of the six months ended June 30, 2024, the group's revenue was approximately RMB 362.9 million, an increase of approximately RMB 101.7 million compared to the six months ended June 30, 2023, an increase of 38.9%. The increase was mainly due to the continuous growth in sales of Boyouno (BA1101) and Boyoubei (BA6101) in China. The net profit for the six months ended June 30, 2024, was RMB 61.7 million, while the net profit for the six months ended June 30, 2023, was RMB.
Express News | Shandong Boan Biotechnology H1 Gross Profit RMB 282.6 Million
Express News | Shandong Boan Biotechnology H1 Net Income RMB 61.7 Million
Express News | Shandong Boan Biotechnology H1 Revenue RMB 362.9 Million
BOAN BIOTECH: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024
Shandong Boan Biotech Announces Corporate Restructure
Boan Biotech (06955.HK) plans to hold a board of directors meeting on August 27 to approve its mid-term performance.
On August 14th, Geruihui announced that Boan Biotech (06955.HK) will hold a board of directors meeting on Tuesday, August 27, 2024 to approve the mid-year performance and release of the company ending on June 30, 2024, and consider the distribution of mid-term dividends (if any).
BOAN BIOTECH: NOTICE OF BOARD MEETING
Shandong Boan Biotechnology Completes Share Placement
Boan Biotech (06955.HK) completed the distribution of a total of 26.66 million shares.
On August 7th, Gelunhui announced that the allotment matters have been completed on August 7th, 2024. A total of 26.66 million new shares (equivalent to about 4.97% of the total number of shares already issued after the issuance and distribution of shares) have been allotted and issued at a distribution price of HKD 9.50 per share to no less than six placing agents.
Shandong Boan Biotechnology Injection Gets FDA OK to Start US Clinical Trials
Bo'an Biotechnology (06955.HK): Dularity injection (BA5101) has been approved for clinical trials in the USA.
On August 5th, Gelunhui announced that the US Food and Drug Administration (FDA) has agreed to the company's self-developed Dulaglutide Injection ("BA5101") to conduct clinical trials in the United States. BA5101 is a biosimilar of Trulicity, which is intended for blood sugar control in type 2 diabetes patients. This product is the first Dulaglutide Injection produced by a Chinese company to be granted clinical trials in the United States. Previously, BA5101 was the first Trulicity biosimilar drug to be declared for listing in China, and its listing application was
Express News | Shandong Boan Biotechnology - Approval Obtained for Initiating Clinical Trials for Dulaglutide Injection (Ba5101) in U.S.
Boan Bio (06955.HK) plans to allocate 26.6556 million shares for a total of HKD 0.253 billion.
On July 31, Glory Hui announced that Boan Bioway (06955.HK) released an announcement about the subscription agreement with the company and the placing agents (UBS Group and AX Capital International) on July 30, 2024. Under the agreement, the placing agents agreed to act as the company's agents to encourage buyers to purchase the placing shares at the placing price according to individual benchmarks (not joint, nor common with the other placing agents) but subject to the terms and conditions of the subscription agreement. The total number of placing shares that may be sold under the placement is 26.6556 million shares, equivalent to approximately 5.23% of the total issued shares as of the date of this announcement; and
Express News | Shandong Boan Biotechnology - Placing Price Is HK$9.50 per Share
Express News | Shandong Boan Biotechnology Co Ltd - Total Number of Placing Shares Sold Under Placing Is 26.7 Mln Shares
Hong Kong stocks move | Boan Biotechnology (06955) rose nearly 5%. Its innovative ADC candidate drug, BA1302, has been approved by the National Medical Products Administration for clinical trials.
Boan Biotech (06955) rose nearly 5%. As of press time, it was up 4.86%, at HK$9.70 with a turnover of HK$3.2403 million.
Analysis
Price Target
No Data
No Data